The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019

Overview

Journal Infect Dis Immun

Specialty Infectious Diseases

Date 2024 Apr 17

PMID 38630075

Authors

Ming Shi

Chao Zhang

Fu-Sheng Wang

Affiliations

Soon will be listed here.

Abstract

Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and SARS-CoV-2 infection (causing coronavirus disease 2019 [COVID-19]) are serious diseases. To date, no effective post-exposure prophylaxis, prevention, or therapeutic agents are recommended as effective for these diseases. Convalescent plasma (CP), donated by individuals with established humoral immunity to the virus after recovering from coronavirus infection, has been successfully applied to treat several infectious diseases, including SARS, MERS, and COVID-19. Nonetheless, there are obstacles and challenges to using CP that should be taken into account. In this review, we summarize the evidence derived from clinical attempts to treat COVID-19 with CP, which represents a promising therapy for severe coronavirus infection. Furthermore, we outline the remaining challenges and general issues that should be considered when using CP treatment for therapeutic or prophylactic purposes.

References

Mahevas M, Tran V, Roumier M, Chabrol A, Paule R, Guillaud C . Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020; 369:m1844. PMC: 7221472. DOI: 10.1136/bmj.m1844. View

Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L . Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020; 158(1):e9-e13. PMC: 7195335. DOI: 10.1016/j.chest.2020.03.039. View

Soo Y, Cheng Y, Wong R, Hui D, Lee C, Tsang K . Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004; 10(7):676-8. PMC: 7129386. DOI: 10.1111/j.1469-0691.2004.00956.x. View

Arabi Y, Hajeer A, Luke T, Raviprakash K, Balkhy H, Johani S . Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016; 22(9):1554-61. PMC: 4994343. DOI: 10.3201/eid2209.151164. View

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A . Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020; 382(24):2327-2336. PMC: 7169476. DOI: 10.1056/NEJMoa2007016. View

Zeng H, Wang D, Nie J, Liang H, Gu J, Zhao A . The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther. 2020; 5(1):219. PMC: 7538052. DOI: 10.1038/s41392-020-00329-x. View

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

10.

Epstein J, Burnouf T . Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang. 2020; 115(6):485-487. PMC: 7264781. DOI: 10.1111/vox.12939. View

11.

Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B . Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020; 136(6):755-759. PMC: 7414593. DOI: 10.1182/blood.2020007079. View

12.

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

13.

Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

14.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

15.

Liu W, Fontanet A, Zhang P, Zhan L, Xin Z, Baril L . Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006; 193(6):792-5. PMC: 7109932. DOI: 10.1086/500469. View

16.

Olivares-Gazca J, Priesca-Marin J, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A . INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY. Rev Invest Clin. 2020; 72(3):159-164. DOI: 10.24875/RIC.20000237. View

17.

Yeh K, Chiueh T, Siu L, Lin J, Chan P, Peng M . Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005; 56(5):919-22. PMC: 7110092. DOI: 10.1093/jac/dki346. View

18.

Kong L . Severe acute respiratory syndrome (SARS). Transfus Apher Sci. 2003; 29(1):101. PMC: 7128968. DOI: 10.1016/s1473-0502(03)00109-5. View

19.

Mair-Jenkins J, Saavedra-Campos M, Baillie J, Cleary P, Khaw F, Lim W . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2014; 211(1):80-90. PMC: 4264590. DOI: 10.1093/infdis/jiu396. View

20.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View